Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 2, 2015, Pages 613-619

  Elmashad, Nehal ^a   Ibrahim, Wesam Salah ^a   Mayah, Wael Wahid ^a   Farouk, Mohamed ^b,c   AboAli, Lobna ^a   Taha, Atef ^a   Elmashad, Wael ^a  

^a TANTA UNIVERSITY   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Hepatocellular carcinoma; IGF 1; Prognosis; Serum factors

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; SOMATOMEDIN C; SORAFENIB; TUMOR MARKER;

ANALOGS AND DERIVATIVES; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; SURVIVAL RATE;

EID: 84925436909     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.2.613     Document Type: Article

References (39)

1. Abdelaziz AO, Elbaz TM, Shousha HI, et al (2014). Survival and prognostic factors for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Asian Pac J Cancer Prev, 15, 3915-20.
2. Beckert S, Farrahi F, Perveen Ghani Q, et al (2006). IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly(ADP-ribose)polymerase. Biochem Biophys Res Commun, 341, 67-72.
3. Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ (2012). Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody. Mol Cancer Ther, 11, 649-59.
4. Carroll VA, Ashcroft M (2006). Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-lindau function: implications for targeting the HIF pathway. Cancer Res, 66, 6264-70.
5. Catrina SB, Botusan IR, Rantanen A, et al (2006): Hypoxiainducible factor-1alpha and hypoxia-inducible factor-2alpha are expressed in kaposi sarcoma and modulated by insulinlike growth factor-I. Clin Cancer Res, 12, 4506-14.
6. Conchillo M, de Knegt RJ, Payeras M, et al (2005) Insulinlike growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol, 43, 630-6.
7. De Meyts P (2004). Insulin and its receptor: structure, function and evolution. Bioessays, 26, 1351-62.
8. Dong MQ, Venable JD, Au N, et al (2007). Quantitative mass spectrometry identifies insulin signaling targets in C. Elegans. Science, 317, 660-3.
9. Gariboldi MB, Ravizza R, Monti E (2010). The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol, 80, 455-62.
10. Höppener JW, de Pagter-Holthuizen P, Geurts van Kessel AH, et al (1985). The human gene encoding insulin-like growth factor I is located on chromosome 12. Hum Genet, 69, 157-60.
11. Jansen M, van Schaik FM, Ricker AT, et al (1983). Sequence of cDNA encoding human insulin-like growth factor I precursor. Nature, 306, 609-11.
12. Jones JI, Clemmons DR (1995). Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev, 16, 3-34.
13. Kaseb AO, Abbruzzese JL, Vauthey JN, et al (2011a). I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology, 80, 373-81.
14. Kaseb AO, Morris JS, Hassan MM, et al (2011b). Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol, 29, 3892-9.
15. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000). The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev, 21, 215-44.
16. Lorenzo-Zuniga V, Bartoli R, Masnou H, et al (2007). Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci, 52, 3245-50.
17. Maki RG (2010). Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol, 28, 4985-95.
18. Mazziotti G, Sorvillo F, Morisco F, et al (2002). Serum insulinlike growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer, 95, 2539-45.
19. Miura Y, Kato H, Noguchi T (1992). "Effect of dietary proteins on insulin like growth factor-1 (IGF-1) messenger ribonucleic acid content in rat liver". Br J Nutr, 67, 257-65.
20. Moser C, Schachtschneider P, Lang SA, et al (2008). Inhibition of insulin-like growth factor-I receptor (IGFIR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer, 44, 1577-86.
21. Ng IO, Lee JM, Srivastava G, Ng M (1998). Expression of insulin-like growth factor II mRNA in hepatocellular carcinoma. J Gastroenterol Hepatol, 13, 152-7.
22. Page EL, Robitaille GA, Pouyssegur J, Richard DE (2002). Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem, 277, 48403-9.
23. Pollak M, Schernhammer ES, Hankinson SE (2004). Insulin-like growth factors and neoplasia. Nature Rev Cancer, 4, 505-18.
24. Pollak M (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nature Rev Cancer, 8, 915-28.
25. Qian J, Yao D, Dong Z, et al (2010). Characteristics of hepatic igf-ii expression and monitored levels of circulating IGF-II mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol, 134, 799-806.
26. Reinmuth N, Liu W, Fan F, et al (2002). Blockade of insulinlike growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res, 8, 3259-69.
27. Sanai FM, Sobki S, Bzeizi KI, et al (2010). Assessment of alphafetoprotein in the diagnosis of hepatocellular carcinoma in Middle Eastern patients. Dig Dis Sci, 55, 3568-75.
28. SCH717454 is reversed by IGF-2 (2012). Mol Cancer Ther, 11, 649-59.
29. Shao YY, Huang CC, Lin SD, Hsu CH, Cheng AL (2012). Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Clin Cancer Res, 18, 3992-7.
30. Shaw RJ, Lamia KA, Vasquez D, et al (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310, 1642-6.
31. Sobrevals L, Rodriguez C, Romero-Trevejo JL, Gondi G, Monreal I, et al. (2010). Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology, 51, 912-21.
32. Steiner DF, Chan SJ, Welsh JM, Kwok SC (1985): Structure and evolution of the insulin gene. Annu Rev Genet, 19, 463-84.
33. Su CH, Lin Y, Cai L (2013). Genetic factors, viral infection, other factors and liver cancer: an update on current progress. Asian Pac J Cancer Prev, 14, 4953-60.
34. Sutton KM, Hayat S, Chau NM, et al (2007). Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. Oncogene, 26, 3920-9.
35. Toyoshima Y, Monson C, Duan C, Wu Y, Gao C, Yakar S, Sadler KC, LeRoith D (2008). The role of insulin receptor signaling in zebrafish embryogenesis. Endocrinology, 149, 5996-6005.
36. Treiber G, Wex T, Rocken C, Fostitsch P, Malfertheiner P (2006). Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol, 132, 699-708.
37. Yang JD, Nakamura I, Roberts LR (2011). The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Sem Cancer Biol, 21, 35-43.
38. Zekri AR, Hassan ZK, Bahnassy AA, et al (2012). Molecular prognostic profile of Egyptian HCC cases infected with hepatitis C virus. Asian Pac J Cancer Prev, 13, 5433-8.
39. Zhou L, Liu C, Meng FD, et al (2012). Long-term prognosis in hepatocellular carcinoma patients after hepatectomy. Asian Pac J Cancer Prev, 13, 483-6.